Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Axilla
Breast Neoplasms
/ drug therapy
Chemotherapy, Adjuvant
/ mortality
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Lymph Node Excision
/ mortality
Mastectomy
/ mortality
Middle Aged
Neoadjuvant Therapy
/ mortality
Prognosis
Receptor, ErbB-2
/ metabolism
Receptors, Estrogen
/ metabolism
Receptors, Progesterone
/ metabolism
Retrospective Studies
Survival Rate
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
28
10
2019
pubmed:
29
1
2020
medline:
3
2
2021
entrez:
29
1
2020
Statut:
ppublish
Résumé
Occult breast cancer (OBC) is a rare clinical entity. Current surgical management includes axillary lymphadenectomy (ALND) with or without mastectomy. We sought to investigate the role of sentinel lymph node biopsy (SLNB) in patients with OBC treated with neoadjuvant chemotherapy (NAC). Patients with clinical T0N+ breast cancer were selected from the National Cancer Data Base (NCDB, 2004-2014) and compared according to axillary surgical approach, SLNB (≤ 4 LNs) or ALND (> 4 LNs). Primary outcome was overall survival (OS), calculated using Kaplan-Meier methods. Secondary outcome was complete pathological response (pCR). A total of 684 patients with OBC were identified: 470 (68.7%) underwent surgery upfront and 214 (31.3%) received NAC. Of the NAC patients, 34 (15.9%) underwent SLNB and 180 (84.1%) ALND. One hundred and fifty-three (72%) patients received radiotherapy (RT). There was no difference in pCR rates between the ALND and SLNB (34.3% vs 24.5%, respectively p = 0.245). In patients undergoing surgery first, improved OS was observed with ALND compared to SLNB (106.9 vs 85.5 months, p = 0.013); however, no difference in OS was found in patients who received NAC (105.6 vs 111.3 months, p = 0.640). RT improved OS in patients who underwent NAC followed by SLNB (RT, 123 months vs no RT, 64 months, p = 0.034). Of NAC patients who did not undergo RT, ALND had superior survival compared to SLNB (113 vs 64 months, p = 0.013). This is the first comparative analysis assessing the surgical management of the axilla in patients with OBC who underwent NAC. In this population, there was a decrease in survival in patients who underwent SLNB alone; however, with the addition of RT, there was no difference in OS between SLNB and ALND. SLNB plus RT may be considered as an alternative to ALND in patients with OBC who have a good response to NAC.
Sections du résumé
BACKGROUND
BACKGROUND
Occult breast cancer (OBC) is a rare clinical entity. Current surgical management includes axillary lymphadenectomy (ALND) with or without mastectomy. We sought to investigate the role of sentinel lymph node biopsy (SLNB) in patients with OBC treated with neoadjuvant chemotherapy (NAC).
METHODS
METHODS
Patients with clinical T0N+ breast cancer were selected from the National Cancer Data Base (NCDB, 2004-2014) and compared according to axillary surgical approach, SLNB (≤ 4 LNs) or ALND (> 4 LNs). Primary outcome was overall survival (OS), calculated using Kaplan-Meier methods. Secondary outcome was complete pathological response (pCR).
RESULTS
RESULTS
A total of 684 patients with OBC were identified: 470 (68.7%) underwent surgery upfront and 214 (31.3%) received NAC. Of the NAC patients, 34 (15.9%) underwent SLNB and 180 (84.1%) ALND. One hundred and fifty-three (72%) patients received radiotherapy (RT). There was no difference in pCR rates between the ALND and SLNB (34.3% vs 24.5%, respectively p = 0.245). In patients undergoing surgery first, improved OS was observed with ALND compared to SLNB (106.9 vs 85.5 months, p = 0.013); however, no difference in OS was found in patients who received NAC (105.6 vs 111.3 months, p = 0.640). RT improved OS in patients who underwent NAC followed by SLNB (RT, 123 months vs no RT, 64 months, p = 0.034). Of NAC patients who did not undergo RT, ALND had superior survival compared to SLNB (113 vs 64 months, p = 0.013).
CONCLUSION
CONCLUSIONS
This is the first comparative analysis assessing the surgical management of the axilla in patients with OBC who underwent NAC. In this population, there was a decrease in survival in patients who underwent SLNB alone; however, with the addition of RT, there was no difference in OS between SLNB and ALND. SLNB plus RT may be considered as an alternative to ALND in patients with OBC who have a good response to NAC.
Identifiants
pubmed: 31989360
doi: 10.1245/s10434-020-08227-w
pii: 10.1245/s10434-020-08227-w
doi:
Substances chimiques
Receptors, Estrogen
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1830-1841Références
Baron PL, Moore M, Kinne DW, et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125(2):210–4.
doi: 10.1001/archsurg.1990.01410140088014
Yang H, Li L, Zhang M, et al. Application of neoadjuvant chemotherapy in occult breast cancer: five case reports. Medicine (Baltimore). 2017;96(40):e8200.
doi: 10.1097/MD.0000000000008200
Macedo FI, Eid J, Flynn J, Jacobs MJ, Mittal VK. Optimal surgical management for occult breast carcinoma: a meta-analysis. Ann Surg Oncol. 2016;23(6):1838–44.
doi: 10.1245/s10434-016-5104-8
Hessler LK, Molitoris JK, Rosenblatt PY, et al. Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the National Cancer Database. Ann Surg Oncol. 2017;24(10):2907–14.
doi: 10.1245/s10434-017-5928-x
Olson JA Jr, Morris E, Van See KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7(6):411–5.
doi: 10.1007/s10434-000-0411-4
National Comprehensive Cancer Network. NCCN Guidelines Version 1. Invasive Breast Cancer. 2018 [cited 2019 March 29].
Walker GV, Smith G, Perkins GH, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116(17):4000–6.
doi: 10.1002/cncr.25197
Miyoshi T, Shiobara M, Watsuki K, et al. Four cases of occult breast cancer treated with breast conserving therapy after neoadjuvant chemotherapy. Gan Kagaku Ryoho. 2017;44(12):1149–51.
Rueth NM, Black D, Limmer AR, et al. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol. 2015;22(1):90–5.
doi: 10.1245/s10434-014-3991-0
Wu SG, Zhang W, Li FY, et al. Comparable survival between additional radiotherapy and local surgery in occult breast cancer after axillary lymph node dissection: a population-based analysis. J Cancer. 2017;8(18):3849–55.
doi: 10.7150/jca.21217
Bilimoria KY, Stewart A, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90.
doi: 10.1245/s10434-007-9747-3
McCartan DP, Zabor E, Morrow M, Van Zee KJ, El-Tamer MB. Oncologic outcomes after treatment for MRI occult breast cancer (pT0N+). Ann Surg Oncol. 2017;24:3141–47.
doi: 10.1245/s10434-017-5965-5
Vlastos G, Jean M, Mirza AN, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001;8(5):425–31.
doi: 10.1007/s10434-001-0425-6
Sohn G, Son B, Lee SJ, et al. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: a nationwide retrospective study. J Surg Oncol. 2014;110(3):270–4.
doi: 10.1002/jso.23644
Khandelwal AK, Garguilo G. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. J Am Surg. 2005;190:609–13.
doi: 10.1016/j.amjsurg.2005.06.026
Fisher B, Brown A, Mamounas E, et al. Effect of properative chemotheray on local regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93.
doi: 10.1200/JCO.1997.15.7.2483
Chehade HEH, Headon H, Tokhy OE, et al. Is sentinal lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg. 2016;212(5):969–81.
doi: 10.1016/j.amjsurg.2016.07.018
Boughey JC, Suman V, Mittendorf EA, et al. Sentinal lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer the ACOSOG Z1071 (Alliance) Clinical Trial. JAMA. 2013;310(14):1455–61.
doi: 10.1001/jama.2013.278932
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.
doi: 10.1016/S1470-2045(13)70166-9
Laughlin BS, Ehsani S, Chalasani P, Gonzalez V. Oncologic outcomes with neoadjuvant chemotherapy and breast conservation for MRI occult breast cancer. Arch Breast Cancer. 2018;5(3):137–42.
Kapoor NS, Sim M, Lin J, et al. Long-term outcome of patients managed with sentinal lymph node biopsy alone for node-negative-invasive breast cancer. Arch Surg. 2012;147(11):1047–52.
doi: 10.1001/archsurg.2012.1563
Gherghe M, Bordea C, Blidaru A. Sentinal lymph node biopsy vs. axillary lymph node dissection in the current surgical treatment of early stage breast cancer. J Med Life. 2015;8(2):176–80.
pubmed: 25866575
pmcid: 4392088
Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.
doi: 10.1056/NEJMoa012782
Boileau J-F, Poirier B, Basik M, Holloway CMB, et al. Sentinal node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258–64.
doi: 10.1200/JCO.2014.55.7827
Mamtani A, Barrio A, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastasis? Results of a prospective study. Ann Surg Oncol. 2016;23:3467–74.
doi: 10.1245/s10434-016-5246-8
Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy. A review. JAMA Oncol. 2017;3(4):549–55.
doi: 10.1001/jamaoncol.2016.4163
Johnson HM, Irish W, Vohra NA, Wong JH. The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): A population analysis. Breast Cancer Res Treat. 2019;177:155–64.
doi: 10.1007/s10549-019-05285-x
Kemeny MM, Rivera D, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152(1):43–7.
doi: 10.1016/0002-9610(86)90135-2
Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet Oncol. 2011;378(9804):1707–16.
doi: 10.1016/S0140-6736(11)61629-2
McGale P, Taylor C, Correa C, et al. Effect of radiotheray after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta analysis of individual patient data for 8135 women in 22 randomized trials. Lancet Oncol. 2014;383(9935):2127–35.
doi: 10.1016/S0140-6736(14)60488-8